title: Influence of melphalan plus fludarabine-conditioning regimen in elderly patients aged ⩾55 years with hematological malignancies.
authors.affiliation: Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Miyao
authors.affiliation: Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Sawa
authors.affiliation: Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Kuwatsuka
authors.affiliation: Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Ozawa
authors.affiliation: Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kato
authors.affiliation: Department of Hematology and Oncology, Konan Kosei Hospital, Konan, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Kohno
authors.affiliation: Division of Hematology, Meitetsu Hospital, Nagoya, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Sao
authors.affiliation: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nishida
authors.affiliation: Department of Hematology, Nagoya Medical Center, Nagoya, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Iida
authors.affiliation: Department of Hematology, Hamamatsu Medical Center, Hamamatsu, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Naito
authors.affiliation: First Department of Internal Medicine, Gifu University, Gifu, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Tsurumi
authors.affiliation: Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Taji
authors.affiliation: Department of Hematology, Fujita Health University, Toyoake, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Mizuta
authors.affiliation: Department of Medical Oncology and Immunology, Nagoya City University, Nagoya, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kusumoto
authors.affiliation: Department of Hematology and Oncology, Mie University, Tsu, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Nakase
authors.affiliation: Department of Hematology and Oncology, Konan Kosei Hospital, Konan, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Morishita
authors.affiliation: Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Kawashima
authors.affiliation: Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Miyamura
authors.affiliation: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Murata
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D064591:Allografts; D018572:Disease-Free Survival; D005260:Female; D019337:Hematologic Neoplasms / Q000401:mortality* / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage*; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D019172:Transplantation Conditioning; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D014740:Vidarabine; C024352:fludarabine; D008558:Melphalan